Leigh Goedeke, PhD will review translational nonhuman primate models of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome, sharing data demonstrating the therapeutic effects of a Controlled-Release Mitochondrial Protonophore (CRMP).
Nonalcoholic fatty liver disease (NAFLD), a condition in which fatty acids accumulate in the liver, can lead to potentially serious conditions including nonalcoholic steatohepatitis (NASH) and type-2 diabetes (T2D). While caloric restriction has been shown to be effective in humans, the strict dietary requirements can be very difficult to maintain in the long-term. Novel therapies are therefore required to reverse NAFLD, insulin resistance and diabetes.
In this webinar hosted by CrownBio, Dr. Leigh Goedeke of Yale University will discuss the development of controlled-release mitochondrial protonophore (CRMP) treatments for NAFLD and type-2 diabetes in diet-induced NHP models of obesity. In addition, she will present data supporting the safety and therapeutic effects of CRMP, including the reversal of hypertriglyceridemia, fatty liver, and hepatic inflammation.
Who Should Attend?
- Preclinical scientists interested in learning more about CRMP and PINTA
- Pharmacological researchers interested in therapies for NAFLD/NASH or type 2 diabetes
- Scientists using NHPs or large animal models to study NAFLD/NASH
Presenters
Leigh Goedeke
Dr. Leigh Goedeke is a Postdoctoral Fellow at Yale School of Medicine, in the laboratory of Dr. Gerald Shulman. With extensive experience in multiple metabolic disease indications, Dr. Goedeke specializes in the interplay between hepatic steatosis, insulin resistance, type 2 diabetes, and cardiovascular disease. As part of the Shulman lab, Dr. Goedeke uses stable isotope tracer methods to understand how alterations in metabolic fluxes contribute to the pathogenesis of insulin resistance and is investigating the therapeutic potential of liver-targeted mitochondrial uncoupling agents to reverse metabolic syndrome.
Sponsor
